Ari BioLab, a KOSDAQ-listed company, announced on the 23rd a decision to raise approximately ₩2 billion through a third-party allocation of newly issued shares. The funds will primarily be used for operational capital. This capital increase will involve the allocation of shares to specific investors, rather than a general public offering. The company did not disclose details regarding the investors involved in the allocation. This move aims to strengthen Ari BioLab’s financial position and support its ongoing business activities. The details of the share allocation and pricing are expected to be announced subsequently. This investment signals continued interest in the biotech sector within the Korean stock market.